New drug aims to speed up recovery from anesthesia muscle relaxants

NCT ID NCT07595393

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This Phase 2 trial tests amogammadex sodium, a drug designed to reverse the effects of common muscle relaxants (rocuronium or vecuronium) used during surgery. About 64 adults having elective surgery will receive the drug at the end of their procedure. Researchers will measure how quickly muscle strength returns and monitor for any side effects. The goal is to find the best dose for future larger studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

amogammadex sodium

What this could lead to

If successful, this could provide a faster, safer way to reverse muscle relaxants after surgery, helping patients recover muscle strength more quickly.

What could go wrong

This is an early Phase 2 dose-finding study with only 64 participants. It may not show clear benefit or could have unexpected side effects. Results may not apply to all surgical patients.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for REVERSING VECURONIUM-INDUCED NEUROMUSCULAR BLOCKADE IN PATIENTS UNDERGOING GENERAL ANESTHESIA SURGERY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.